Evolent Health, Inc. Announces Pricing of Oversubscribed and Upsized $145.0 Million of Convertible Senior Notes Due 2031 to Repurchase Existing Notes and Class A Common Stock

Rhea-AI Summary

Evolent Health (NYSE:EVH) has announced the pricing of $145.0 million of 4.50% convertible senior notes due 2031, with an option for an additional $21.75 million. The notes are convertible into cash, shares, or a combination at an initial conversion price of $13.53 per share, representing a 50% premium over the closing price.

The company will use approximately $100.2 million of the proceeds to repurchase $167.4 million of its existing 2025 Notes, and $40.0 million to repurchase shares at $9.02 per share. The transaction is expected to save over $9 million in annual interest expense while minimizing shareholder dilution with an effective conversion premium exceeding 130%.

Positive

• Expected savings of over $9 million in annual interest expense
• Extended debt maturity profile with no maturities until 2029
• 50% conversion premium on new notes indicates confidence in share price appreciation
• Oversubscribed offering suggests strong investor interest
• Strategic debt restructuring reduces interest burden while minimizing dilution

Negative

• Significant increase in total debt with $145 million new notes issuance
• Potential future dilution if shares trade above conversion price
• Higher 4.50% interest rate on new notes compared to 1.50% on 2025 notes
• Share repurchase at $9.02 could impact available cash for operations

Insights

Capital Markets Specialist

Evolent's $145M convertible notes offer reduces interest expense by $9M annually while extending debt maturities to 2029 with minimal dilution risk.

Evolent Health has successfully priced an oversubscribed and upsized $145 million convertible senior notes offering due 2031, with a 4.50% interest rate. The initial conversion price of $13.53 represents a substantial 50% premium over the current share price, indicating strong investor confidence despite current market conditions.

The strategic financial maneuver accomplishes several key objectives. First, it enables Evolent to repurchase approximately $167.4 million of its 1.50% convertible notes due 2025, effectively extending its debt maturity profile with no obligations now until 2029. Second, the company will concurrently repurchase 4.43 million shares at $9.02 per share, neutralizing potential dilution from the new convertible offering.

Most significantly, this refinancing will reduce Evolent's annual interest expense by over $9 million compared to retiring the 2025 notes using their committed credit facilities. The structure creates an effective conversion premium exceeding 130% when accounting for the share repurchase, substantially minimizing dilution risk to existing shareholders.

The transaction's upsizing from $140 million to $145 million with a $21.75 million greenshoe option reflects strong institutional demand. The notes contain favorable terms including conversion rights termination provisions that protect against dilution unless the stock price substantially appreciates, requiring 150% of conversion price before August 2028 and 130% thereafter.

This refinancing strengthens Evolent's balance sheet flexibility while maintaining its capital allocation priority of debt reduction, positioning the company for potentially accretive growth opportunities while reducing near-term financial pressure.

WASHINGTON, Aug. 19, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions ("Evolent"), today announced the pricing of $145.0 million aggregate principal amount of 4.50% convertible senior notes due 2031. The notes are being offered only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Evolent has also granted the initial purchasers in the offering a 30-day option to purchase up to an additional $21.75 million aggregate principal amount of notes. Evolent has increased the size of the offering from $140.0 million to $145.0 million (or $166.75 million if the initial purchasers' option to purchase additional notes is exercised in full).

Key terms of the transactions include:

• Interest on the notes is payable semiannually in arrears on February 15 and August 15 of each year, beginning on February 15, 2026, at a rate equal to 4.50% per annum. The notes will mature on August 15, 2031, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date.
• The notes are convertible into cash, shares of Evolent's Class A common stock, or a combination of cash and shares of Evolent's Class A common stock, at Evolent's election based on an initial conversion rate of 73.9098 shares of Class A common stock per $1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately $13.53 per share of Class A common stock. The initial conversion price represents a premium of approximately 50.0% over the closing price of the Class A common stock on the New York Stock Exchange on August 18, 2025.
• Evolent has agreed to repurchase 4.43 million shares of its Class A common stock sold short by initial investors in the offering in privately negotiated transactions effected with or through one of the initial purchasers or its affiliate at a purchase price per share equal to the last reported sale price of Evolent's Class A common stock on August 18, 2025, which was $9.02 per share.

John Johnson, Evolent's Chief Financial Officer, stated, "This transaction helps Evolent avoid over $9 million of annual interest expense when compared to retiring the 2025 notes with our committed incremental credit facilities, while minimizing shareholder dilution with an effective conversion premium over 130% as a result of the concurrent share repurchase, assuming the initial purchasers' option to purchase additional notes is exercised in full.  After the retirement of our 2025 notes, Evolent has no maturities until 2029, and we remain committed to our stated capital allocation priority of deploying cash generation to paying down debt."

Subject to satisfaction of certain conditions and subject to Evolent's ability to terminate the conversion rights on or after August 20, 2026 as described below, the notes will be convertible at the option of the holders at any time prior to the close of business on the business day immediately preceding the maturity date.

On or after August 20, 2026, Evolent may terminate the conversion rights of the notes if (i) for any conversion rights termination date occurring on or after August 20, 2026 and prior to, but not including, August 21, 2028, the last reported sale price of Evolent's Class A common stock has been at least 150% of the conversion price for at least 20 trading days during the 30 consecutive trading day period (including the last trading day of such period) prior to Evolent's delivery of notice of such termination of conversion rights or (ii) for any conversion rights termination date occurring on or after August 21, 2028, the last reported sale price of Evolent's Class A common stock has been at least 130% of the conversion price for at least 20 days during the 30 consecutive trading day period (including the last trading day of such period) prior to Evolent's delivery of notice of such termination of conversion rights.

Holders of the notes may require Evolent to repurchase their notes upon the occurrence of a "fundamental change" (as defined in the indenture that will govern the notes) at a price equal to 100% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest. Evolent may not redeem the notes unless and until holders' conversion rights have been terminated at its election. However, if holders' conversion rights have been terminated, Evolent may redeem for cash all or a portion of the notes at a redemption price equal to 100% of the principal amount of the notes being redeemed, plus any accrued and unpaid interest.

Evolent estimates that the net proceeds from the offering will be approximately $140.2 million (or approximately $161.2 million if the initial purchasers exercise their option to purchase additional notes in full), after deducting fees and estimated expenses payable by Evolent.

Evolent expects to use approximately $100.2 million of the net proceeds from the offering, plus available liquidity, to repurchase approximately $167.4 million aggregate principal of its 1.50% convertible senior notes due 2025 (the "2025 Notes") for approximately $167.6 million in cash in note repurchases entered into concurrently with the pricing of the notes. Evolent also expects to use approximately $40.0 million of the net proceeds from the offering to repurchase shares of Evolent's Class A common stock concurrently with the pricing of the offering in privately negotiated transactions. If the initial purchasers exercise their option to purchase additional notes, Evolent expects to use the net proceeds from the sale of the additional notes to reduce the amount of available liquidity required to repurchase or repay the 2025 Notes.

In connection with the concurrent share repurchase described above, Evolent has agreed to repurchase shares of its Class A common stock sold short by initial investors in the offering in privately negotiated transactions effected with or through one of the initial purchasers or its affiliate at a purchase price per share equal to the last reported sale price of Evolent's Class A common stock on August 18, 2025, which was $9.02 per share. These repurchases could increase (or reduce the size of any decrease in) the market price of Evolent's Class A common stock or the notes. In the case of repurchases effected concurrently with the offering, this activity could affect the market price of Evolent's Class A common stock prior to, concurrently with or shortly after the pricing of the notes, and could result in a higher effective conversion price for the notes.

In connection with the repurchases of the 2025 Notes described above, Evolent expects that holders of the 2025 Notes who agree to have their 2025 Notes repurchased and who have hedged their equity price risk with respect to such 2025 Notes will unwind all or part of their hedge positions by buying Evolent's Class A common stock and/or entering into or unwinding various derivative transactions with respect to Evolent's Class A common stock. This activity could increase (or reduce the size of any decrease in) the market price of Evolent's Class A common stock, including concurrently with or shortly after the pricing of the notes, resulting in a higher effective conversion price of the notes. Evolent cannot predict the magnitude of such market activity or the overall effect it will have on the price of the notes or Evolent's Class A common stock and the corresponding effect on the initial conversion price of the notes.

Consummation of the sale of the notes is subject to customary closing conditions, and there can be no assurance that the offering of the notes will be consummated. Settlement is expected to occur on August 21, 2025.

The notes and any shares of Class A common stock of Evolent issuable upon conversion of the notes will not be registered under the Securities Act or any state securities laws, and unless so registered, may not be offered or sold in the United States, except pursuant to an exemption from the registration requirements of the Securities Act and applicable state securities laws.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities law of any such jurisdiction.

About Evolent

Evolent (NYSE: EVH) specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable. Evolent serves a national base of leading payers and providers and is consistently recognized as a top place to work in health care nationally.

Contact:

investorrelations@evolent.com

Forward-Looking Statements - Cautionary Language

Certain statements made in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). A forward-looking statement is a statement that is not a historical fact and, without limitation, includes any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like: "believe," "anticipate," "expect," "estimate," "aim," "predict," "potential," "continue," "plan," "project," "will," "should," "shall," "may," "might" and other words or phrases with similar meaning in connection with a discussion of future operating or financial performance. In particular, these include statements relating to future actions, trends in our businesses, prospective services, future performance or financial results, and the closing of pending transactions and the outcome of contingencies, such as legal proceedings. The company intends such forward-looking statements to be covered under the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act. By their nature, forward-looking statements are subject to numerous factors, risks and uncertainties that could cause actual outcomes and results to be materially different from those projected. These risks and uncertainties are discussed under the headings "Forward-Looking Statements - Cautionary Language," and "Risk Factors," in the company's Annual Report on Form 10-K for the year ended December 31, 2024, which is on file with the U.S. Securities and Exchange Commission (the "SEC"), and in the company's other filings with the SEC, including its Quarterly Reports on Form 10-Q for the periods ended March 31, 2025 and June 30, 2025, filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statements were made. Except for any ongoing obligation to disclose material information as required by the United States federal securities laws, the company does not have any intention or obligation to publicly update or revise any forward-looking statements after issuing this release, whether to reflect any future events or circumstances or otherwise.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/evolent-health-inc-announces-pricing-of-oversubscribed-and-upsized-145-0-million-of-convertible-senior-notes-due-2031-to-repurchase-existing-notes-and-class-a-common-stock-302533122.html

SOURCE Evolent Health, Inc.

FAQ

What is the interest rate and maturity date of EVH's new convertible notes?

The new convertible notes carry a 4.50% interest rate and will mature on August 15, 2031, with interest payable semiannually on February 15 and August 15.

What is the conversion price for Evolent Health's 2031 convertible notes?

The initial conversion price is $13.53 per share, representing a 50% premium over the August 18, 2025 closing price, with a conversion rate of 73.9098 shares per $1,000 principal amount.

How will EVH use the proceeds from the convertible notes offering?

EVH will use $100.2 million to repurchase existing 2025 Notes and $40.0 million to repurchase shares of Class A common stock, with additional proceeds if the overallotment option is exercised.

What is the expected annual interest savings for Evolent Health from this transaction?

The transaction is expected to help Evolent avoid over $9 million in annual interest expense compared to retiring the 2025 notes with incremental credit facilities.

When can holders convert the EVH 2031 convertible notes?

The notes are convertible at any time until maturity, but Evolent may terminate conversion rights after August 20, 2026, subject to specific stock price conditions.